» Articles » PMID: 15778742

GW274150 and GW273629 Are Potent and Highly Selective Inhibitors of Inducible Nitric Oxide Synthase in Vitro and in Vivo

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2005 Mar 22
PMID 15778742
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

1 GW274150 ([2-[(1-iminoethyl) amino]ethyl]-L-homocysteine) and GW273629 (3-[[2-[(1-iminoethyl)amino]ethyl]sulphonyl]-L-alanine) are potent, time-dependent, highly selective inhibitors of human inducible nitric oxide synthase (iNOS) vs endothelial NOS (eNOS) (>100-fold) or neuronal NOS (nNOS) (>80-fold). GW274150 and GW273629 are arginine competitive, NADPH-dependent inhibitors of human iNOS with steady state K(d) values of <40 and <90 nM, respectively. 2 GW274150 and GW273629 inhibited intracellular iNOS in J774 cells in a time-dependent manner, reaching IC(50) values of 0.2+/-0.04 and 1.3+/-0.16 microM, respectively. They were also acutely selective in intact rat tissues: GW274150 was >260-fold and 219-fold selective for iNOS against eNOS and nNOS, respectively, while GW273629 was >150-fold and 365-fold selective for iNOS against eNOS and nNOS, respectively. 3 The pharmacokinetic profile of GW274150 was biphasic in healthy rats and mice with a terminal half-life of approximately 6 h. That of GW273629 was also biphasic in rats, producing a terminal half-life of approximately 3 h. In mice however, elimination of GW273629 appeared monophasic and more rapid (approximately 10 min). Both compounds show a high oral bioavailability (>90%) in rats and mice. 4 GW274150 was effective in inhibiting LPS-induced plasma NO(x) levels in mice with an ED(50) of 3.2+/-0.7 mg kg(-1) after 14 h intraperitoneally (i.p.) and 3.8+/-1.5 mg kg(-1) after 14 h when administered orally. GW273629 showed shorter-lived effects on plasma NO(x) and an ED(50) of 9+/-2 mg kg(-1) after 2 h when administered i.p. 5 The effects of GW274150 and GW273629 in vivo were consistent with high selectivity for iNOS, as these inhibitors were of low potency against nNOS in the rat cerebellum and did not cause significant effects on blood pressure in instrumented mice.

Citing Articles

Endoplasmic reticulum stress and expression of nitric oxide synthases in heart failure with preserved and with reduced ejection fraction - pilot study.

Momot K, Wojciechowska M, Krauz K, Czarzasta K, Puchalska L, Zarebinski M Cardiol J. 2024; 31(6):885-894.

PMID: 39360989 PMC: 11706269. DOI: 10.5603/cj.97962.


Advancements in the Research of New Modulators of Nitric Oxide Synthases Activity.

Maccallini C, Budriesi R, De Filippis B, Amoroso R Int J Mol Sci. 2024; 25(15).

PMID: 39126054 PMC: 11313090. DOI: 10.3390/ijms25158486.


-Ethyl-Isothiocitrullin-Based Dipeptides and 1,2,4-Oxadiazole Pseudo-Dipeptides: Solid Phase Synthesis and Evaluation as NO Synthase Inhibitors.

Mauchauffee E, Leroy J, Chamcham J, Ejjoummany A, Maurel M, Nauton L Molecules. 2023; 28(13).

PMID: 37446746 PMC: 10343299. DOI: 10.3390/molecules28135085.


Nitric Oxide/Nitric Oxide Synthase System in the Pathogenesis of Neurodegenerative Disorders-An Overview.

Iova O, Marin G, Lazar I, Stanescu I, Dogaru G, Nicula C Antioxidants (Basel). 2023; 12(3).

PMID: 36979000 PMC: 10045816. DOI: 10.3390/antiox12030753.


Nitroglycerin as a model of migraine: Clinical and preclinical review.

Sureda-Gibert P, Romero-Reyes M, Akerman S Neurobiol Pain. 2023; 12:100105.

PMID: 36974065 PMC: 10039393. DOI: 10.1016/j.ynpai.2022.100105.


References
1.
Hobbs A, Higgs A, Moncada S . Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol. 1999; 39:191-220. DOI: 10.1146/annurev.pharmtox.39.1.191. View

2.
Charles I, Scorer C, Moro M, Fernandez C, Chubb A, Dawson J . Expression of human nitric oxide synthase isozymes. Methods Enzymol. 1996; 268:449-60. DOI: 10.1016/s0076-6879(96)68047-1. View

3.
Chatterjee P, Patel N, Sivarajah A, Kvale E, Dugo L, Cuzzocrea S . GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003; 63(3):853-65. DOI: 10.1046/j.1523-1755.2003.00802.x. View

4.
Russell R . Use of arginine analogs as inhibitors of nitric oxide synthase in rat-aortic rings. Methods Mol Biol. 2000; 100:243-50. DOI: 10.1385/1-59259-749-1:243. View

5.
Morrison J, WALSH C . The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol. 1988; 61:201-301. DOI: 10.1002/9780470123072.ch5. View